
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs3.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD41E4AC192A45000033A90B7F9091.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="bmccanc" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10557167/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="BMC Cancer" /><meta name="citation_title" content="Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide" /><meta name="citation_author" content="Craig A. Vincent" /><meta name="citation_author_institution" content="Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author_institution" content="Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author" content="Itzel Nissen" /><meta name="citation_author_institution" content="Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author_institution" content="Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author" content="Soran Dakhel" /><meta name="citation_author_institution" content="Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author_institution" content="Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author" content="Andreas H&#x000f6;rnblad" /><meta name="citation_author_institution" content="Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author" content="Silvia Remeseiro" /><meta name="citation_author_institution" content="Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_author_institution" content="Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden" /><meta name="citation_publication_date" content="2023" /><meta name="citation_volume" content="23" /><meta name="citation_doi" content="10.1186/s12885-023-11418-9" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10557167/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10557167/" /><meta name="citation_pmid" content="37803333" /><meta name="DC.Title" content="Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="BMC" /><meta name="DC.Contributor" content="Craig A. Vincent" /><meta name="DC.Contributor" content="Itzel Nissen" /><meta name="DC.Contributor" content="Soran Dakhel" /><meta name="DC.Contributor" content="Andreas H&#x000f6;rnblad" /><meta name="DC.Contributor" content="Silvia Remeseiro" /><meta name="DC.Date" content="2023" /><meta name="DC.Identifier" content="10.1186/s12885-023-11418-9" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide" /><meta property="og:type" content="article" /><meta property="og:description" content="Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10557167/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/16/">BMC Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/425102/">v.23; 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10557167
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10557167/pdf/12885_2023_Article_11418.pdf" class="int-view">PDF (3.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10557167/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10557167/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10557167" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="k1242Y845XPq5tUK2OFYMjwSQvGe59uZrJ3mVsa6wAt9nbNpk1mlrHZ5kYCVSbN6">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F&amp;text=Epigenomic%20perturbation%20of%20novel%20EGFR%20enhancers%20reduces%20the%20proliferative%20and%20invasive%20capacity%20of%20glioblastoma%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37803333/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37803333/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10557167/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/16/">BMC Cancer</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/425102/">v.23; 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10557167
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><a href="//doi.org/10.1186%2Fs12885-023-11418-9" title="Link to Publisher's site" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A"><img src="/corehtml/pmc/pmcgifs/logo-bmccanc.png" alt="Logo of bmccanc"><!-- --></img></a></div>
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">BMC Cancer.</span> 2023; 23: 945. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Oct 6. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1186%2Fs12885-023-11418-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/s12885-023-11418-9</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10557167</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37803333">37803333</a></div></div></div><h1 class="content-title">Epigenomic perturbation of novel <em>EGFR</em> enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vincent%20CA%5BAuthor%5D" class="affpopup" co-rid="_co_idm139733317778432" co-class="co-affbox">Craig A. Vincent</a>,<sup>1,</sup><sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nissen%20I%5BAuthor%5D" class="affpopup" co-rid="_co_idm139733309471488" co-class="co-affbox">Itzel Nissen</a>,<sup>1,</sup><sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dakhel%20S%5BAuthor%5D" class="affpopup" co-rid="_co_idm139733309468672" co-class="co-affbox">Soran Dakhel</a>,<sup>1,</sup><sup>2</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=H&#x000f6;rnblad%20A%5BAuthor%5D" class="affpopup" co-rid="_co_idm139733309465856" co-class="co-affbox">Andreas H&#x000f6;rnblad</a>,<sup>1</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Remeseiro%20S%5BAuthor%5D" class="affpopup" co-rid="_co_idm139733313061024" co-class="co-affbox">Silvia Remeseiro</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1,</sup><sup>2</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139733317778432"><h3 class="no_margin">Craig A. Vincent</h3><p><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><p><sup>2</sup>Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vincent%20CA%5BAuthor%5D">Craig A. Vincent</a></div></div><div id="_co_idm139733309471488"><h3 class="no_margin">Itzel Nissen</h3><p><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><p><sup>2</sup>Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nissen%20I%5BAuthor%5D">Itzel Nissen</a></div></div><div id="_co_idm139733309468672"><h3 class="no_margin">Soran Dakhel</h3><p><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><p><sup>2</sup>Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dakhel%20S%5BAuthor%5D">Soran Dakhel</a></div></div><div id="_co_idm139733309465856"><h3 class="no_margin">Andreas H&#x000f6;rnblad</h3><p><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=H&#x000f6;rnblad%20A%5BAuthor%5D">Andreas H&#x000f6;rnblad</a></div></div><div id="_co_idm139733313061024"><h3 class="no_margin">Silvia Remeseiro</h3><p><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><p><sup>2</sup>Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Remeseiro%20S%5BAuthor%5D">Silvia Remeseiro</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139733314748352_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139733314748352_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139733314748352_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139733314748352_ai" style="display:none"><div class="fm-affl" id="Aff1"><sup>1</sup>Ume&#x000e5; Centre for Molecular Medicine (UCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </div><div class="fm-affl" id="Aff2"><sup>2</sup>Wallenberg Centre for Molecular Medicine (WCMM), Ume&#x000e5; University, Ume&#x000e5;, Sweden </div><div><span class="fm-affl">Silvia Remeseiro, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="es.umu@oriesemer.aivlis" class="oemail">es.umu@oriesemer.aivlis</a></span>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes hide half_rhythm" id="idm139733314748352_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Mar 23; Accepted 2023 Sep 18.</div></div><div class="permissions half_rhythm hide" id="idm139733314748352_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; The Author(s) 2023</div><div class="license half_rhythm"><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Additional file 1: Supplementary Figure 1.</strong> Recruitment of dCas9-KRAB repressor complex leads to enrichment of H3K9me3 at specic targeted sites in U251 cells. A-F, Bar charts depicting the enrichment of H3K9me3, as determined by ChIP-qPCR, at each genomic region (i.e., CE5B, CE6B, CE8, Promoter) and in each of the <em>EGFR</em> enhancer-repressed lines: iCE5B (B), iCE6B (C), iCE5B+6B (D) and iCE8 (E), alongside the iPromoter (F) and control line (A). <strong>Supplementary Figure 2.</strong> CRISPRi of <em>EGFR</em> enhancer CE5B+6B in Human Glioblastoma cell line U3013 downregulates <em>EGFR</em> gene expression, reduces cell proliferation rate, and sensitises cells to temozolomide (TMZ). A, <em>EGFR</em> gene expression as determined by RT-qPCR. B, Proliferation rates of the iCE5B+6B and promoter-repressed U3013 cell lines determined by live-cell imaging. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t=0 and presented as mean &#x000b1; SEM (<em>n</em>=3). Statistical significance was assessed by unpaired <em>t</em> test (* <em>P</em> &#x0003c; 0.05, ** <em>P</em> &#x0003c; 0.01). C-D, Proliferation rates of control U3013 and iCE5B+6B enhancer-repressed U3013 cells determined by live-cell imaging upon treatment with 125&#x003bc;M TMZ in comparison with the DMSO-treated control. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t=0h and represented as mean &#x000b1; SEM (<em>n</em>=4). <em>P</em> values were determined by unpaired t test. <strong>Supplementary Figure 3.</strong> CRISPR/Cas9-mediated deletion of <em>EGFR</em> enhancers in U251 cells downregulates <em>EGFR</em> gene expression and affects cell proliferation rates. A, Genotyping PCR of the <em>EGFR</em> enhancer-deleted cell lines (&#x00394;CE5B, &#x00394;CE6B, &#x00394;CE5B+6B, &#x00394;CE8) alongside the &#x00394; Promoter and empty vector control lines (left), and schematic outline of the PCR genotyping strategy (right). Note that the wild-type CE5B+6B allele is too large to be amplied under these conditions. Full uncropped gel image presented in Supplementary Figure 6. B, <em>EGFR</em> gene expression levels relative to <em>HPRT</em> in <em>EGFR</em> enhancer-deleted cell lines as determined by RT-qPCR assays. Data is represented as mean &#x000b1; SEM (<em>n</em>=3). Statistical significance as assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (* <em>P</em> &#x0003c; 0.05, ** <em>P</em> &#x0003c; 0.01). C, Cropped western blots showing EGFR protein expression and normalised to GAPDH protein levels (full uncropped blots in Supplementary Figure 6). D, Proliferation rates of cell lines carrying <em>EGFR </em>enhancer deletions or promoter deletions as determined by live-cell imaging, and in comparison to the empty vector control line. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t= 0h and plotted as mean &#x000b1; SEM (<em>n</em>=3). <strong>Supplementary Figure 4.</strong> CRISPRi of the <em>EGFR</em> enhancer CE5B+6B and promoter compromises the invasive capacity of U251 cells. A, Representative images of the fusion between the fetal brain spheroids and the GFP+ tumour spheres generated from control, iCE5B+6B and iPromoter lines. Scale bars 750&#x000b5;m (0h) and 300&#x000b5;m (2-24h). B, Quantication of fusion events across a pool of independent tumour sphere/brain spheroid confrontation assays (<em>n</em>=10). C, Quantication of invasion frequency between the GFP+ tumour spheres and brain spheroids between 0h and 96h. D, Representative images of invasion/non-invasion between GFP+ tumour spheres and brain spheroids. Scale bar 100&#x000b5;m. Arrowheads point to areas of invasion. E-F, Line plots comparing the rate at which the respective cell lines migrate either from media containing 1%&#x000a0;FBS to 1%&#x000a0;FBS (no-chemoattractant negative control) or from 1%&#x000a0;FBS to 10%&#x000a0;FBS (chemoattractant condition). Migration was assessed by live-cell imaging taking images every hour and migration rate was determined by automatic quantification of the area of migrated cells. Data is represented as mean &#x000b1; SEM (<em>n</em>=3). <strong>Supplementary Figure 5.</strong> Expression of key metabolic genes in the <em>EGFR</em> enhancer-repressed iCE5B+6B cell line. A, Results from qPCR analysis where certain metabolic genes are upregulated in the iCE5B+6B line relative to the control. Gene expression levels are relative to <em>HPRT</em>. <strong>Supplementary Figure 6.</strong> Uncropped western blot and gel images. A-B, Western blot on repressed cell lines (A) and deletion cell lines (B) detecting EGFR and GAPDH expression. Cropped images presented in Figure 1G and Supplementary Figure 3C, respectively. C, Uncropped genotyping gel from enhancer-deletion U251 cell lines. Cropped image presented in Supplementary Figure 3A.</div><div><a href="/pmc/articles/PMC10557167/bin/12885_2023_11418_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl">12885_2023_11418_MOESM1_ESM.pdf</a><span style="color:gray"> (121M)</span></div><div class="small guid">GUID: D3EA73EF-F52C-4B55-B3B7-88FD72E146B8</div></div></dd></dl><dl data-length="502" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>Data depicted on Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>A is available: a) via the UCSC browser for the tracks displaying the GeneHancer interactions and H3K27ac on 7 ENCODE cell lines, or b) retrieved from GEO (Gene Expression Omnibus) with the accession number <a class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE217349" ref="/geo/query/acc.cgi?acc=GSE217349"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE217349","term_id":"217349"}}</span>GSE217349</a> for the tracks displaying H3K27ac and ATAC in the glioblastoma lines U3008, U3031 and U3039. Other materials can be available from the corresponding author, SR, upon reasonable request.</p></dd></dl></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="sec-a.h.b.n.a" class="sec sec-first"><h3 id="sec-a.h.b.n.atitle">Background</h3><p id="Par1" class="p p-first-last">Glioblastoma (GB) is the most aggressive of all primary brain tumours and due to its highly invasive nature, surgical resection is nearly impossible. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of&#x02009;~&#x02009;14&#x000a0;months. Alterations in the Epidermal Growth Factor Receptor gene (<em>EGFR</em>) are common in GB tumours, but therapies targeting EGFR have not shown significant clinical efficacy.</p></div><div id="sec-a.h.b.n.b" class="sec"><h3 id="sec-a.h.b.n.btitle">Methods</h3><p id="Par2" class="p p-first-last">Here, we investigated the influence of the <em>EGFR</em> regulatory genome on GB cells and identified novel <em>EGFR</em> enhancers located near the GB-associated SNP rs723527. We used CRISPR/Cas9-based approaches to target the <em>EGFR</em> enhancer regions, generating multiple modified GB cell lines, which enabled us to study the functional response to enhancer perturbation.</p></div><div id="sec-a.h.b.n.c" class="sec"><h3 id="sec-a.h.b.n.ctitle">Results</h3><p id="Par3" class="p p-first-last">Epigenomic perturbation of the <em>EGFR</em> regulatory region decreases <em>EGFR</em> expression and reduces the proliferative and invasive capacity of glioblastoma cells, which also undergo a metabolic reprogramming in favour of mitochondrial respiration and present increased apoptosis. Moreover, <em>EGFR</em> enhancer<em>-</em>perturbation increases the sensitivity of GB cells to TMZ, the first-choice chemotherapeutic agent to treat glioblastoma.</p></div><div id="sec-a.h.b.n.d" class="sec"><h3 id="sec-a.h.b.n.dtitle">Conclusions</h3><p id="Par4" class="p p-first-last">Our findings demonstrate how epigenomic perturbation of <em>EGFR</em> enhancers can ameliorate the aggressiveness of glioblastoma cells and enhance the efficacy of TMZ treatment. This study demonstrates how CRISPR/Cas9-based perturbation of enhancers can be used to modulate the expression of key cancer genes, which can help improve the effectiveness of existing cancer treatments and potentially the prognosis of difficult-to-treat cancers such as glioblastoma.</p></div><div id="sec-a.h.b.n.e" class="sec sec-last"><h3 id="sec-a.h.b.n.etitle">Supplementary Information</h3><p class="p p-first-last">The online version contains supplementary material available at 10.1186/s12885-023-11418-9.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text"><em>EGFR</em>, Enhancer, Glioblastoma, Epigenomic perturbation, CRISPR/Cas9</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Introduction</h2><p id="Par5" class="p p-first">Glioblastoma (GB), also known as grade 4 astrocytoma, is a common and highly aggressive type of primary brain tumour, for which survival rates have not significantly improved in recent decades (median survival&#x02009;~&#x02009;14&#x000a0;months, 5-year survival&#x02009;&#x0003c;&#x02009;5%) [<a href="#CR1" rid="CR1" class=" bibr popnode">1</a>, <a href="#CR2" rid="CR2" class=" bibr popnode">2</a>]. Due to its highly invasive nature, complete surgical resection is nearly impossible [<a href="#CR3" rid="CR3" class=" bibr popnode">3</a>] and therefore recurrence is inevitable. While the addition of tumour-treating fields (TTFields) following chemoradiotherapy has led to extended survival [<a href="#CR4" rid="CR4" class=" bibr popnode">4</a>, <a href="#CR5" rid="CR5" class=" bibr popnode">5</a>], the treatment is not widely available due largely to cost-efficiency concerns [<a href="#CR6" rid="CR6" class=" bibr popnode">6</a>], and in the countries where it is applied, only 30% of patients are eligible and therefore receive this treatment option [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>, <a href="#CR8" rid="CR8" class=" bibr popnode">8</a>]. Hence, the current standard of care for GB patients consists of radiotherapy and concomitant chemotherapy with temozolomide (TMZ), often preceded by tumour debulking surgery. Temozolomide (TMZ) is a DNA alkylating agent commonly used in the treatment of glioblastoma as adjuvant to radiotherapy. Patients with methylated <em>MGMT</em> (O6-methylguanine-DNA methyltransferase) promoter respond with better outcome to TMZ treatment given the role of MGMT in DNA damage repair [<a href="#CR9" rid="CR9" class=" bibr popnode">9</a>&#x02013;<a href="#CR11" rid="CR11" class=" bibr popnode">11</a>], which highlights the relevance of epigenomic cues in the patient outcome upon treatment.</p><p id="Par6">In fact, GB remains a difficult-to-treat cancer due to the high degree of inter- and intra-tumour heterogeneity and the complexity of genetic, epigenetic and microenvironment events. One of the key challenges in treating glioblastoma is the ability of cancer cells to evade the effects of chemotherapy and radiation therapy. This is often due to the over-expression of certain genes, such as <em>EGFR</em>, which can promote the survival and proliferation of cancer cells. The Epidermal Growth Factor Receptor gene (<em>EGFR</em>) is one of the most frequently altered genes in glioblastoma. 57% of tumours display some form of alteration in <em>EGFR</em> [<a href="#CR12" rid="CR12" class=" bibr popnode">12</a>] and among the classical subtype, <em>EGFR</em> is overexpressed in more than 95% [<a href="#CR13" rid="CR13" class=" bibr popnode">13</a>]. Moreover, high <em>EGFR</em> expression in gliomas correlates with reduced overall survival in patients [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>]. Constitutive activation of the EGFR signalling pathway can occur through overexpression of the receptor itself or its ligand, through amplification of the <em>EGFR</em> locus (which includes non-coding regions), or through coding mutations (e.g. EGFRvIII). All of which result in increased cell proliferation, invasive capacity, survival and angiogenic potential.</p><p id="Par7">While the traditional focus of cancer research has been on the impact of coding mutations, Genome-Wide Association Studies (GWAS) have revealed that most genetic variants that predispose to cancer are located within non-coding genomic regions with potential to act as <em>cis</em>-regulatory elements (e.g. enhancers) [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>]. Enhancers are stretches of DNA that regulate transcription in a spatiotemporal manner, through their capacity to bind transcription factors (TFs) and protein complexes that control gene expression. In the linear genome, enhancers can be located vast distances from the gene promoter which they act upon, but they require close physical proximity in the 3D nuclear space to exert their regulatory function [<a href="#CR16" rid="CR16" class=" bibr popnode">16</a>, <a href="#CR17" rid="CR17" class=" bibr popnode">17</a>]. Enhancer dysfunction due to genetic, topological or epigenetic mechanisms can contribute to human diseases, including cancer. However, accurate identification of enhancers and understanding their role in disease still remains a challenge [<a href="#CR18" rid="CR18" class=" bibr popnode">18</a>].</p><p id="Par8" class="p p-last">In the context of glioblastoma, the mechanistic contribution of the non-coding regulatory genome to pathogenesis remains understudied. Here, we identify novel <em>EGFR</em> enhancer elements in the vicinity of the known GB-associated single nucleotide polymorphism (SNP) rs723527, and we functionally dissect their regulatory potential by introducing CRISPR-based (epi-)genomic perturbations. Targeting these <em>EGFR</em> enhancer regions in glioblastoma cells leads to decreased proliferation and migration rates, due in part to an increased rate of apoptosis, which could be triggered by an underlying metabolic reprogramming of these cells. Thus, targeting these novel <em>EGFR</em> enhancers diminishes the malignancy of glioblastoma cells by reducing their proliferative and invasive capacity, and sensitising them to treatment with TMZ. Our findings highlight the association between <em>EGFR</em> expression and temozolomide efficacy, and demonstrate how CRISPR/Cas9-based targeting of enhancers can be used to modulate the expression of key cancer genes. Combining (epi-)genomic perturbation of enhancers with existing cancer treatments can improve their effectiveness and subsequently the prognosis of glioblastoma and other cancers difficult to treat.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Methods and materials</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Cell culture</h3><div id="Sec4" class="sec sec-first"><h4 id="Sec4title">Cell lines</h4><p id="Par9" class="p p-first"><em>U251 MG human glioblastoma cell line</em> (Sigma-Aldrich, #09063001, authenticated by short tandem repeat (STR)-PCR profiling) were grown in EMEM (EBSS) supplemented with 2&#x000a0;mM Glutamine, 1% NEAA (Non-Essential Amino Acids), 1&#x000a0;mM Sodium Pyruvate, 10% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin (all from Gibco). HEK293T cells were grown in DMEM/F-12 GlutaMAX&#x02122;-Supplemented media containing 10% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin (all from Gibco).</p><p id="Par10" class="p p-last"><em>U3013 human glioblastoma cell line</em> was established from a GB-patient surgical sample and obtained via the Human Glioblastoma Cell Culture (HGCC) resource (Uppsala University, Sweden). Cells were seeded onto poly-ornithine/laminin-coated plates and grown in Feed Medium [1:1 ratio of DMEM/F12 Glutamax (Gibco) and Neurobasal medium (Gibco), supplemented with 1X B27 (Gibco), 1X N-2 Supplement (Gibco), 1% penicillin/ streptomycin (Gibco), 10&#x000a0;ng/ml EGF (Epithelial Growth Factor; PreproTech EC Ltd.) and 10&#x000a0;ng/ml FGF (Fibroblast Growth Factor; PeproTech EC Ltd)].</p></div><div id="Sec5" class="sec sec-last"><h4 id="Sec5title">Tumour spheres and brain spheroids</h4><p id="Par11" class="p p-first">3D tumour spheres were generated by culturing cells from the <em>EGFR</em> iCE5B&#x02009;+&#x02009;6B, iPromoter and control (&#x02205;) lines in 1.5% agarose-coated flasks at a density of 2&#x02013;3&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/flask for 8&#x000a0;days. Chick fetal brain spheroids were generated as previously described [<a href="#CR19" rid="CR19" class=" bibr popnode">19</a>]. Briefly, brains were dissected from E12 embryos obtained from fertilized Bovan chicken eggs, and dissociated mechanically and enzymatically (accutase, 5&#x000a0;min). Isolated brain cells were seeded in 1.5% agarose-coated flasks (10<sup>6</sup> cells per 25cm<sup>2</sup> flask) and grown in RPMI medium supplemented with 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin (all from Gibco). 3D spheroid invasion assays were performed on 8-well chamber slides (Ibidi) by placing one tumour sphere and one brain spheroid per well, and either monitored with a EVOS M5000 imaging system over 24&#x000a0;h to assess fusion or imaged on a Leica widefield Thunder microscope at t&#x02009;=&#x02009;96&#x000a0;h to determine invasion.</p><p id="Par12" class="p p-last">All cells were grown in a cell incubator at 37&#x000a0;&#x000b0;C in a humidified atmosphere (95% humidity) with 5% CO<sub>2</sub>.</p></div></div><div id="Sec6" class="sec"><h3 id="Sec6title">Luciferase dual-reporter assay</h3><p id="Par13" class="p p-first-last">Luciferase assay was performed using the Promega Dual-Luciferase&#x000ae; Reporter Assay System following manufacturer&#x02019;s instructions. Conserved Elements (CE) were PCR-amplified from GB genomic DNA using GoTaq&#x000ae; G2 DNA Polymerase (Promega #M7845) (primer sequences listed in Supplementary Table S<a href="#MOESM1" rid="MOESM1" class=" media">1</a>) and cloned into pGL4.23[luc2/minP] vector (Promega Cat# E8411) using Acc65I and BglII restriction enzymes (Thermo Fisher). pGL4.23&#x02009;+&#x02009;enhancer constructs were transfected into the U251 cells using Lipofectamine&#x02122; 2000 Transfection Reagent (Thermo Fisher) together with the pRL-SV40 vector (Promega Cat# E2231) for signal normalisation. pGL4.13[luc2/SV40] vector (Promega Cat# E6681) served as a positive control. Luminescence readings were taken using the Biotek Synergy HT microplate reader. Data was represented as fold change (FC) over empty pGL4.23 readings.</p></div><div id="Sec7" class="sec"><h3 id="Sec7title">ChIP (Chromatin ImmunoPrecipitation)-qPCR</h3><p id="Par14" class="p p-first-last">ChIP-qPCR was performed in stable glioblastoma lines established upon epigenomic perturbation of the <em>EGFR</em> enhancers, including the empty vector control lines, and in the parental U251 GB cell line. Briefly, cells were fixed on the plate by adding formaldehyde directly to the medium (final concentration 1% formaldehyde) for 15&#x000a0;min at room temperature while rotating. The crosslinking reaction was quenched by adding Glycine (final concentration 125&#x000a0;mM Glycine) for 5&#x000a0;min, and fixed cells were scraped off and harvested in 1X cold PBS containing protease inhibitors. Cells were then resuspended in lysis buffer (3&#x02013;6&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/ml) and sonicated in a Covaris E220 instrument (shearing time 12&#x000a0;min, PIP 140, duty factor 5, 200 cycles per burst). Chromatin immunoprecipitation was performed with antibodies against H3K27ac (Abcam Cat# ab4729), H3K27me3 (Abcam Cat# ab192985) and H3K9me3 (Abcam Cat# ab8898) and using Dynabeads&#x02122; M-280 Sheep Anti-Rabbit IgG (Invitrogen Cat# 11203D). Chromatin Immunoprecipated DNA was amplified by qPCR using a CFX Connect Real-Time PCR Detection System (Bio-Rad) and primers specific for the genomic regions of interest (Supplementary Table S<a href="#MOESM1" rid="MOESM1" class=" media">2</a>). Positive and negative regions were measured in parallel for control purposes and enrichment was calculated over the input.</p></div><div id="Sec8" class="sec"><h3 id="Sec8title">Generation of stable cell lines</h3><div id="Sec9" class="sec sec-first"><h4 id="Sec9title">Cloning</h4><p id="Par15" class="p p-first-last">The UCSC genome browser (<a href="http://genome.ucsc.edu" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://genome.ucsc.edu</a>) tool &#x02018;CRISPR target identifier&#x02019; was used to select CRISPR gRNAs. For CRISPRi, gRNAs targeting central regions of the CEs were cloned into the <em>pLV hU6-sgRNA hUbC-dCas9-KRAB-T2a-GFP</em> plasmid (Addgene_71237) using the BsmBI restriction sites (gRNA sequences listed in Supplementary Table S<a href="#MOESM1" rid="MOESM1" class=" media">3</a>). To generate genomic deletions, we modified this plasmid and cloned gRNAs targeting the flanks of the CEs. First, we replaced the dCas9-KRAB with an active Cas9 coding sequence, and further replaced GFP by mCherry, thus generating two new constructs hereby named <em>pLV hU6-sgRNA hUbC-Cas9-T2a-GFP</em> and <em>pLV hU6-sgRNA hUbC-Cas9-T2a-mCherry.</em> Deletion gRNAs were then cloned into these vectors. GFP and mCherry expression enabled subsequent FACS sorting of positively transduced cells.</p></div><div id="Sec10" class="sec"><h4 id="Sec10title">Lentivirus transduction</h4><p id="Par16" class="p p-first-last">Lentiviral particles were produced and collected upon transfection of HEK293T cells with the lentiviral Cas9 or dCas9 plasmids expressing the gRNAs, along with the psPAX2 (Addgene_12260) and pMD2.G (Addgene_12259) lentiviral packaging plasmids and using Lipofectamine&#x02122; 2000 (Thermo Fisher). Between 24&#x02013;48&#x000a0;h post-transfection, the viral supernatant was filtered, supplemented with 20&#x000a0;mM HEPES and polybrene (10&#x000a0;&#x000b5;g/ml), and used for transduction of U251 or U3013 cells in three rounds.</p></div><div id="Sec11" class="sec"><h4 id="Sec11title">FACS sorting</h4><p id="Par17" class="p p-first-last">To establish stable lines, transduced cells were sorted by Fluorescence-Activated Cell Sorting (FACS) using the BD FACSAria&#x02122; III Cell Sorter instrument and the BD FACSDiva software. For CRISPRi experiments, GFP positive cells were collected and, in the case of CRISPR/Cas9-mediated genomic deletions double positive GFP&#x02009;+&#x02009;mCherry&#x02009;+&#x02009;cells were sorted and further expanded.</p></div><div id="Sec12" class="sec sec-last"><h4 id="Sec12title">Validation of cell lines</h4><p id="Par18" class="p p-first-last">Repression by CRISPRi was validated by measuring the enrichment of H3K9me3 by ChIP-qPCR (see methods section above). Genomic deletions were confirmed by genotyping PCR using primers designed to flank the gRNA target sequences. Genomic DNA (gDNA) was extracted using Qiagen DNeasy Blood &#x00026; Tissue Kit (ID: 69504) and genotyping PCRs were performed using GoTaq&#x000ae; G2 DNA Polymerase (Promega #M7845) (genotyping primers are listed in Supplementary Table S<a href="#MOESM1" rid="MOESM1" class=" media">4</a>).</p></div></div><div id="Sec13" class="sec"><h3 id="Sec13title">RT-qPCR</h3><p id="Par19" class="p p-first-last">Total RNA was extracted from cells using the RNeasy Plus Mini Kit (ID: 74,134, Qiagen). cDNA was synthesised using RevertAid H Minus Reverse Transcriptase (Thermo Fisher&#x000a0;#EP0451) and random hexamers (Thermo Fisher&#x000a0;#SO142), following the manufacturer&#x02019;s instructions. Quantitative-PCR analysis was performed with CFX Connect Real-Time PCR Detection System (Bio-Rad) using SYBR green master mix&#x02014;PowerUp (Thermo Fisher). Gene expression levels were measured alongside the housekeeping gene <em>HPRT</em> for normalisation (qPCR primers listed in Supplementary Table S<a href="#MOESM1" rid="MOESM1" class=" media">5</a>). Relative expression levels were determined using the &#x00394;&#x00394;Ct method.</p></div><div id="Sec14" class="sec"><h3 id="Sec14title">Western blot</h3><p id="Par20" class="p p-first-last">Whole cell protein extracts were prepared using lysis buffer containing 2% SDS and 0.1&#x000a0;M Tris&#x02013;HCl pH 6.8. Protein concentration was measured using the Pierce&#x02122; BCA Protein Assay Kit (Thermo Scientific) and absorbance at 560&#x000a0;nm was determined using the Biosan HiPo MPP-96 microplate photometer. Protein samples were loaded into precast gels, run in the Mini-PROTEAN Tetra Cell and blotted using the Trans-Blot&#x000ae; Turbo&#x02122; Transfer System (all Bio-Rad) according to standard protocols. Primary antibodies against EGFR (1:1000, rabbit, Cell Signaling Cat# 4267) and GAPDH (1:1000, rabbit, Cell Signaling Cat# 2118) were diluted in 5% bovine serum albumin (BSA) in Tris-Buffered Saline 0.1% Tween&#x000ae; 20 Detergent. Peroxidase AffiniPure Goat Anti-Rabbit IgG (H&#x02009;+&#x02009;L) (1:10,000, Jackson ImmunoResearch Labs Cat# 111&#x02013;035-003) was used for detection together with Bio-Rad Clarity Western ECL Substrate. ChemiDoc&#x02122; MP Imaging System with Image Lab&#x02122; Software (Bio-Rad) was used for signal detection and quantification.</p></div><div id="Sec15" class="sec"><h3 id="Sec15title">Live-cell imaging</h3><p id="Par21" class="p p-first">All live-cell imaging experiments were performed using the IncuCyte S3 Live-Cell Analysis instrument (Sartorius) and the image analysis was performed using the Incucyte Base Analysis Software.</p><div id="Sec16" class="sec"><h4 id="Sec16title">Proliferation assays</h4><p id="Par22" class="p p-first-last">Cell proliferation was determined by live-cell imaging taking phase-contrast images every 4&#x000a0;h during a period of 72&#x000a0;h. Automated cell segmentation and counting was performed with the adherent Cell-by-Cell analysis software module. Data was normalised to the t&#x02009;=&#x02009;0&#x000a0;h count and presented as ratios.</p></div><div id="Sec17" class="sec"><h4 id="Sec17title">Scratch wound assays</h4><p id="Par23" class="p p-first-last">Scratch wound assays were performed using the IncuCyte Wound Maker tool on cells seeded in ImageLock 96-well plates (Cat No 4379). Phase-contrast images were taken every 2&#x000a0;h and gap closure was determined as confluence measurements obtained with the automated Scratch Wound Analysis Software Module.</p></div><div id="Sec18" class="sec"><h4 id="Sec18title">Chemotactic migration assays</h4><p id="Par24" class="p p-first-last">Chemotactic migration was determined by imaging cells in the Incucyte&#x000ae; Clearview 96-Well Chemotaxis Plate (#4582), and analysed using the Chemotaxis Analysis Software Module. Cells were seeded in 1%&#x000a0;FBS media in the trans-well insert and 10%&#x000a0;FBS media was used as chemoattractant in the reservoir wells to stimulate migration of cells. A no-chemoattractant negative control was set up using 1% FBS in both the insert and reservoir wells.</p></div><div id="Sec19" class="sec"><h4 id="Sec19title">Annexin V apoptosis assays</h4><p id="Par25" class="p p-first-last">Incucyte&#x000ae; Annexin V Red Dye (Sartorius #4641) was added to the cell culture medium at a final dilution of 1:200 (as per product guidelines). Both phase-contrast and red fluorescence (Excitation: 567&#x02013;607&#x000a0;nM, Emission 622&#x02013;704&#x000a0;nM) images were taken every 4&#x000a0;h during a period of 72&#x000a0;h. A red area confluence mask was applied to the cells to measure the apoptotic cell area using the Incucyte Base Analysis Software. Data was expressed as red area confluence (%) and normalised to total cell count (red area/total phase area).</p></div><div id="Sec20" class="sec"><h4 id="Sec20title">Reactive oxygen species</h4><p id="Par26" class="p p-first-last">5&#x000a0;&#x000b5;M CellROX&#x02122; Deep Red Reagent (Invitrogen #<a id="__tag_1142058783" class="tag_hotlink" href="/nuccore/C10422" ref="/nuccore/C10422"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"C10422","term_id":"1535493","term_text":"C10422"}}</span>C10422</a>) was added to cells in culture. After 30&#x000a0;min of incubation time at 37&#x000a0;&#x000b0;C, the reagent was washed out twice with PBS and the cells were immediately imaged. Both phase-contrast and red fluorescence (Excitation: 567&#x02013;607&#x000a0;nM, Emission 622&#x02013;704&#x000a0;nM) images were taken. A mask was applied to the red fluorescent signal to measure integrated intensity (normalised to phase-contrast cell count).</p></div><div id="Sec21" class="sec sec-last"><h4 id="Sec21title">Temozolomide treatment</h4><p id="Par27" class="p p-first-last">U251 and U3013 cells were treated with 1&#x000a0;mM TMZ and 125&#x000a0;&#x000b5;M TMZ, respectively (Temozolomide, Sigma-Aldrich T2577, dissolved in DMSO (Dimethyl Sulfoxide, Calbiochem&#x02014;CAS 67&#x02013;68-5). Cell proliferation was assessed in comparison to DMSO-treated control cells as above (see <em>Proliferation assays</em>). The TMZ concentrations used for each line were experimentally determined by serial titration, such as that the highest concentration not impacting the proliferation of the control (&#x02205;) lines was chosen.</p></div></div><div id="Sec22" class="sec"><h3 id="Sec22title">Immunofluorescence</h3><p id="Par28" class="p p-first-last">For immunofluorescence, cells were cultured as described above, fixed in 4% formaldehyde for 15&#x000a0;min at room temperature, permeabilized in 0.2% Triton-X100 for 5&#x000a0;min and subjected to incubation with an anti-cleaved caspase-3 antibody (Cell Signaling #9661). Images were taken using a Leica widefield Thunder microscope.</p></div><div id="Sec23" class="sec"><h3 id="Sec23title">Measurement of mitochondrial function</h3><p id="Par29" class="p p-first-last">Mitochondrial function was determined using the Seahorse XFe96 Analyzer (Agilent), which measures mitochondrial oxygen flux and extracellular acidification rate for live cells in real time. The Cell Mitochondrial Stress Test was performed following manufacturer&#x02019;s instructions and oxygen consumption rates (OCR) were determined. Seahorse 96 well-plates were coated with Poly-D-lysine (50&#x000a0;&#x000b5;g/ml, ThermoFisher Scientific, Cat# A3890401) and 20,000 cells were seeded per well. The test was performed as per standard protocol in XF assay medium (Dulbecco's Modified Eagle Medium (DMEM)&#x02009;+&#x02009;5&#x000a0;mM glucose&#x02009;+&#x02009;2&#x000a0;mM glutamine&#x02009;+&#x02009;1&#x000a0;Mm pyruvate, pH7.4). 20&#x000a0;&#x000b5;M of oligomycin, 10&#x000a0;&#x000b5;M of FCCP and 5&#x000a0;&#x000b5;M rotenone&#x02009;+&#x02009;5&#x000a0;&#x000b5;M Antimycin A were added to selectively inhibit different steps of mitochondrial respiration and thus initiate the relevant phases of the test. ATP production was calculated as (basal respiration &#x02013; proton leak). Spare Respiratory Capacity (SRC) was determined as (maximal respiration &#x02013; basal respiration).</p></div><div id="Sec24" class="sec"><h3 id="Sec24title">Measurement of glutathione (GSH-to-GSSG) ratios</h3><p id="Par30" class="p p-first-last">The GSH/GSSG-Glo&#x02122; Assay (Promega #V6611) was used to measure GSH/GSSG ratios and therefore infer oxidative stress levels (i.e., lower GSH/GSSG ratios are indicative of oxidative stress). 5,000 cells per well were seeded in white opaque 96-well plates and treated as per standard protocol. Luminescence readings were taken with the Biotek Synergy HT microplate reader using a 1&#x000a0;s integration time.</p></div><div id="Sec25" class="sec sec-last"><h3 id="Sec25title">Statistical analysis</h3><p id="Par31" class="p p-first-last">All statistical analysis was performed using GraphPad Prism software. Statistical tests, multiple comparison correction methods, number of replicates and significance are indicated in figure legends and in the corresponding figure panels. Figure legends also indicate the cases when the Welch&#x02019;s correction method was chosen to not assume equal SDs between groups.</p></div></div><div id="Sec26" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec26title">Results</h2><div id="Sec27" class="sec sec-first"><h3 id="Sec27title">Identification of novel <em>EGFR</em> enhancers in glioblastoma</h3><p id="Par32" class="p p-first">We first identified a panel of 10 conserved elements (CE1-CE10) as potential candidates to regulate the expression of <em>EGFR</em> in glioblastoma. This identification was based on sequence conservation and <em>GeneHancer</em> prediction to interact with the <em>EGFR</em> promoter, together with our previous data on distribution of active chromatin marks and chromatin accessibility (Chakraborty et al. bioRxiv 10.1101/2022.11.16.516797.) (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>A). Two SNPs associated with increased GB risk are located in the <em>EGFR</em> locus: rs723527, within intron 1, and rs75061358,&#x02009;~&#x02009;150&#x000a0;kb upstream of the <em>EGFR</em> transcription start site (TSS) [<a href="#CR20" rid="CR20" class=" bibr popnode">20</a>]. Of these, rs723527 is located within one of these conserved elements (CE5), in a highly accessible region and enriched in the active enhancer mark H3K27ac in a panel of patient-derived glioblastoma cell lines (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>A and Chakraborty et al. bioRxiv 10.1101/2022.11.16.516797.). In contrast, rs75061358 is not located within one of the CEs and does not display any features indicative of enhancer activity. We made similar observations regarding the distribution of chromatin marks around these SNPs in U251 glioblastoma cells, as measured by ChIP-qPCR (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>B). In particular subregions CE5C and CE6B, which are proximal to the SNP rs723527, displayed enrichment of the active enhancer mark H3K27ac and depletion of the repressive mark H3K27me3.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139733356881040"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10557167_12885_2023_11418_Fig1_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12885_2023_11418_Fig1_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10557167/bin/12885_2023_11418_Fig1_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139733356881040"><a target="object" rel="noopener" href="/pmc/articles/PMC10557167/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Fig. 1</a></div><!--caption a7--><div class="caption"><p>Identification of novel <em>EGFR</em> enhancers in glioblastoma located in the vicinity of the GB-associated SNP rs723527. <strong>A</strong>, Schematic representation of the <em>EGFR</em> gene locus displaying: GB-associated SNPs; <em>GeneHancer</em> predicted interactions between genomic regions and the <em>EGFR</em> promoter; H3K27ac enrichment in seven ENCODE cell lines; H3K27ac enrichment and chromatin accessibility by ATAC-seq across three representative patient-derived GB cell lines (our previous data Chakraborty et al<em>.</em> bioRxiv doi.org/10.1101/2022.11.16.516797); and the conserved elements (CE) selected for characterisation highlighted in grey. Visualisation in the UCSC genome browser. <strong>B</strong>, Enrichment of H3K27ac and H3K27me3 in U251 glioblastoma cells around the CE regions as determined by ChIP-qPCR. <strong>C</strong>, Enhancer dual-luciferase reporter assay. Luciferase activity relative to the control reporter plasmid is expressed as a fold change. Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;5). <strong>D</strong>, Schematic representation of the deletion and repression CRISPR-perturbation strategies. <strong>E</strong>, Enrichment of H3K9me3 upon expression of the transcriptional repressor KRAB in the CRISPRi-repressed U251 cell lines as determined by ChIP-qPCR. <strong>F</strong>, <em>EGFR</em> gene expression relative to <em>HPRT</em> in each KRAB-repressed U251 line (i.e. iCEx) as determined by RT-qPCR. Data is represented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;4). Statistical significance was assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01). <strong>G</strong>, Cropped results from western blot, displaying EGFR and GAPDH protein expression (full uncropped blots in Supplementary Fig.&#x000a0;<a href="#MOESM1" rid="MOESM1" class=" media">6</a>)</p></div></div></div><p id="Par33" class="p p-last">To determine the regulatory potential of these 10 conserved elements (CEs), we employed luciferase reporter assays in U251 cells. For large CEs (&#x0003e;&#x02009;2&#x000a0;kb), smaller regions were subcloned and tested (e.g. CE5 A, B and C regions). CE6B and CE8 retained the highest regulatory potential on enhancer reporter assays (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>C), where CE6B is located closest to the GB-associated SNP rs723527. In contrast, CEs located close to rs75061358 did not demonstrate enhancer activity in these reporter assays. These findings therefore highlight three putative enhancer elements: CE5, CE6 and CE8, which are located within intron 1 of <em>EGFR</em> and in close proximity to rs723527.</p></div><div id="Sec28" class="sec"><h3 id="Sec28title">CRISPR-perturbation of novel <em>EGFR</em> enhancers decreases <em>EGFR</em> gene expression and protein levels</h3><p id="Par34" class="p p-first-last">To functionally demonstrate that the identified CEs act as <em>EGFR</em> enhancers in glioblastoma, we introduced targeted perturbations utilising both CRISPRi (dCas9-KRAB) and CRISPR/Cas9. We generated various U251 glioblastoma cell lines with either stable epigenomic repression of the CEs or carrying the deletions of interest (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>D) and validated our key findings in an independent GB cell line, U3013, more recently established by the HGCC (the Human Glioblastoma Cell Culture). As expected, upon recruitment of the transcriptional repressor KRAB to the CEs, the established lines showed an enrichment of the repressive mark H3K9me3 in the corresponding region, in comparison to the empty vector control line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>E, Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">1</a>A-F). dCas9-KRAB repression of the CEs (hereby iCE) correlated with significant downregulation of <em>EGFR</em> gene expression in both U251 and U3013 cell lines (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>F, Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">2</a>A), and lower protein levels (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>G). For iCE5B, iCE5B&#x02009;+&#x02009;6B and the iPromoter region, <em>EGFR</em> gene expression levels were significantly reduced to 44%, 53% and 43% of the expression observed in the control line, respectively (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>F). Similarly, protein levels were reduced to 49%, 41% and 58% of the control line levels (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>G). Only in the case of iCE8, the level of repression indicated by enrichment of H3K9me3 was not sufficient to considerably diminish the EGFR protein levels<em>.</em> Furthermore, the cell lines carrying genomic deletions (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">3</a>A) also present a significant downregulation of <em>EGFR</em> gene expression accompanied by reduced protein levels (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">3</a>B, C). In the &#x00394;CE5B&#x02009;+&#x02009;6B, &#x00394;CE6B, &#x00394;CE8 and &#x00394;Promoter lines, <em>EGFR</em> expression is reduced to 29%, 48%, 66% and 70% of the control line levels, respectively (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">3</a>B). Therefore, CRISPR-based perturbation of the CEs with regulatory potential demonstrates, in a functional manner, that they act as <em>EGFR</em> enhancers in the context of glioblastoma.</p></div><div id="Sec29" class="sec"><h3 id="Sec29title">Repressing the <em>EGFR</em> enhancers reduces the proliferative and invasive capacity of glioblastoma cells</h3><p id="Par35" class="p p-first">Having determined the impact of enhancer perturbation on <em>EGFR</em> expression, we then evaluated the proliferative and invasive capacities of the enhancer-perturbed glioblastoma lines. Firstly, we assessed cell proliferation by live-cell imaging using the IncuCyte S3 live-cell analysis instrument and automated cell counting software. Cell lines with independent repression of CE5B and CE6B displayed a modest reduction in their proliferative capacity in comparison to the control (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>A). However, CRISPRi of the large region comprising CE5B&#x02009;+&#x02009;6B, which includes the SNP rs723527, significantly reduced the cell proliferation of glioblastoma cells to almost the same extent as the <em>EGFR</em> promoter-repressed cell line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>A, B). The same effect was observed in the U3013 iCE5B&#x02009;+&#x02009;6B cell line (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">2</a>B). CRISPR/Cas9-mediated deletion of the <em>EGFR</em> enhancers demonstrated slight inhibition of proliferation, though statistically insignificant, in all cell lines carrying the enhancer deletions (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">3</a>D). The proliferative defect observed in the enhancer-repressed cell lines is much stronger than that of the enhancer-deletion lines, likely due to the spreading of the repressive marks over a larger region. Together with the added advantage that CRISPRi with dCas9-KRAB does not involve direct modification of the DNA sequence but solely epigenomic editing, we focused our further investigation on the <em>EGFR</em> enhancer-repressed glioblastoma cell lines.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139733314526032"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10557167_12885_2023_11418_Fig2_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12885_2023_11418_Fig2_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10557167/bin/12885_2023_11418_Fig2_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139733314526032"><a target="object" rel="noopener" href="/pmc/articles/PMC10557167/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Fig. 2</a></div><!--caption a7--><div class="caption"><p>CRISPRi of novel <em>EGFR</em> enhancers reduces the proliferation and migration of U251 glioblastoma cells. <strong>A</strong>, Proliferation rates of the <em>EGFR</em> enhancer-repressed lines determined by live-cell imaging. Images were acquired every 4&#x000a0;h and proliferation was determined by automatic cell count. Data is normalised to t&#x02009;=&#x02009;0 and presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;4). Statistical significance was assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01, *** <em>P</em>&#x02009;&#x0003c;&#x02009;0.001). <strong>B</strong>, Representative images of control cells alongside iCE5B&#x02009;+&#x02009;6B and iPromoter cell lines at t&#x02009;=&#x02009;0&#x000a0;h and t&#x02009;=&#x02009;72&#x000a0;h. <strong>C</strong>, Images showing gap closure rate of control, iCE5B&#x02009;+&#x02009;6B and iPromoter cells at 0&#x000a0;h and 24&#x000a0;h. Yellow area represents the gap area at each time point, and blue area highlights the migration area. <strong>D</strong> Gap closure rate (%) between 0 and 24&#x000a0;h. Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;5). Statistical significance was assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05, ** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01). <strong>E</strong>, Schematic representation of the chemotactic migration assay. <strong>F</strong>, Representative images from the chemotactic assays taken at t&#x02009;=&#x02009;2&#x000a0;h and t&#x02009;=&#x02009;48&#x000a0;h. Masked area (blue) covers cells that migrated through the pores of the culture plate towards the chemoattractant. <strong>G</strong> Relative migration rates of iCE5B&#x02009;+&#x02009;6B and iPromoter cell lines represented as total masked area of migrated cells at t&#x02009;=&#x02009;24&#x000a0;h, t&#x02009;=&#x02009;36&#x000a0;h and t&#x02009;=&#x02009;48&#x000a0;h, normalised to the initial seeding density. Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). <em>P</em> values were determined by unpaired <em>t</em> test (** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01, *** <em>P</em>&#x02009;&#x0003c;&#x02009;0.001)</p></div></div></div><p id="Par36" class="p p-last">Next, we assessed the invasive capacity of the <em>EGFR</em> enhancer-repressed lines through different approaches. In scratch wound healing assays, we observed that the iCE5B&#x02009;+&#x02009;6B and iPromoter cells were migrating towards the gap at a significantly lower rate than the control (&#x02205;) U251 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>C, D). This data shows that epigenomic repression of the <em>EGFR</em> CE5B&#x02009;+&#x02009;6B enhancer and promoter results in a decreased migrative capacity. We also observed that <em>EGFR</em> enhancer-repressed tumour spheres tend to display a reduced fusion and invasion capacity, when confronted with chick brain spheroids in 3D spheroid invasion assays (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">4</a>A-D). In addition, we determined the invasive capacity of the <em>EGFR</em> enhancer-repressed lines by measuring their migration rate towards a chemical stimulus in chemotaxis migration assays. In these trans-well chemotactic assays, cells migrate through cell-permeable pores attracted by higher concentration of nutrients (i.e., from 1 to 10% FBS) and are monitored in real-time (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>E). As a negative control, a no-chemoattractant condition was established (i.e., 1% to 1% FBS) (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">4</a>E-G). We observed that the migrative capacity of the iCE5B&#x02009;+&#x02009;6B cell line was significantly compromised (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>F-G), similar to that observed upon repression of the <em>EGFR</em> promoter. Altogether, these findings show that repressing the <em>EGFR</em> enhancer region CE5B&#x02009;+&#x02009;6B, which encompasses the GB-associated SNP rs723527, leads to significantly decreased proliferation, migration and invasion of glioblastoma cells.</p></div><div id="Sec30" class="sec"><h3 id="Sec30title">Reduced malignancy of the <em>EGFR</em>-enhancer repressed GB cells can be linked to increased apoptosis and mitochondrial respiration</h3><p id="Par37" class="p p-first">We further characterised the <em>EGFR-</em>enhancer repressed lines by firstly measuring their relative apoptosis rates over time by live-cell imaging of cell cultures in the presence of annexin V red dye. The apoptotic cells (i.e., annexin V positive area) in the iCE5B&#x02009;+&#x02009;6B repressed GB line increased at a significantly faster rate compared to the control cell line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>A, D). The rate of apoptosis within the individually repressed CE5B and CE6B cell lines does not significantly differ from the unmodified control cells, and interestingly, nor does the promoter-repressed cell line. This effect is also observed when we account for differences in proliferation rate by normalising the annexin V-positive area to the total cell population area. We observed that after 48 and 72&#x000a0;h in culture, the percentage of annexin V-positive area in the iCE5B&#x02009;+&#x02009;6B cell line is significantly higher than that of the control line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>B, C). In line with this, the iCE5B&#x02009;+&#x02009;6B cells also display a higher percentage of cleaved caspase-3 positive cells than the control line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>E). This altogether suggests that targeting the CE5B&#x02009;+&#x02009;6B enhancer region specifically causes an apoptotic response which cannot be triggered by repressing the promoter of <em>EGFR.</em></p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139733318704800"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10557167_12885_2023_11418_Fig3_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12885_2023_11418_Fig3_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10557167/bin/12885_2023_11418_Fig3_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139733318704800"><a target="object" rel="noopener" href="/pmc/articles/PMC10557167/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Fig. 3</a></div><!--caption a7--><div class="caption"><p>Epigenomic perturbation of the <em>EGFR</em> enhancer CE5B&#x02009;+&#x02009;6B in U251 cells triggers apoptosis and favours mitochondrial respiration. <strong>A</strong>, Apoptosis levels in the <em>EGFR</em> enhancer-repressed lines as determined by annexin V red fluorescence area (% confluence) measured at 4-h intervals. Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). <em>P</em> values were determined by unpaired <em>t</em> test with Welch&#x02019;s correction (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05). <strong>B</strong>-<strong>C</strong>, Apoptosis rate represented as proportion of the area occupied by annexin V red apoptotic cells <em>vs</em> total cells at t&#x02009;=&#x02009;48&#x000a0;h (<strong>B</strong>) and t&#x02009;=&#x02009;72&#x000a0;h (<strong>C</strong>). Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). Statistical significance was determined by unpaired <em>t</em> test (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05, ** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01). <strong>D</strong>, Representative phase-contrast images of control cells and iCE5B&#x02009;+&#x02009;6B cells alongside annexin V-positive cells (red) to identify apoptotic cells at t&#x02009;=&#x02009;0&#x000a0;h and t&#x02009;=&#x02009;72&#x000a0;h. <strong>E</strong>, Percent of cleaved caspase-3 positive cells, determined by immunofluorescence, after 48&#x000a0;h culture time in 1%&#x000a0;FBS. Data is plotted as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;6,&#x02009;&#x0003e;&#x02009;100 cells per image). <em>P</em> values were determined by unpaired <em>t</em> test (**** <em>P</em>&#x02009;&#x0003c;&#x02009;0.0001). <strong>F</strong>, Schematic representation of the Agilent Seahorse XF Cell Mito Stress Test. <strong>G</strong>, Oxygen Consumption Rate (OCR) of control cells and iCE5B&#x02009;+&#x02009;6B enhancer-repressed cells in response to the assay compounds. Data is plotted as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). <strong>H</strong>-<strong>J</strong>, Basal and maximal respiration (<strong>H</strong>), ATP production (<strong>I</strong>) and spare respiratory capacity (<strong>J</strong>) of control cells and iCE5B&#x02009;+&#x02009;6B enhancer-repressed cells as determined by Cell Mito Stress Test. <em>P</em> values were determined by unpaired <em>t</em> test (** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01, **** <em>P</em>&#x02009;&#x0003c;&#x02009;0.0001). <strong>K</strong>, Levels of reactive oxygen species (ROS) in control and iCE5B&#x02009;+&#x02009;6B cells represented as integrated red fluorescent intensity per cell count. Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). Statistical significance assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05). <strong>L,</strong> Oxidative stress, determined by the ratio of reduced (GSH) and oxidised glutathione (GSSG). Data is presented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). <em>P</em> values were determined by unpaired <em>t</em> test (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05)</p></div></div></div><p id="Par38" class="p p-last">Cancer cell metabolism is a key factor contributing to the cells&#x02019; ability to evade apoptosis. In order to examine whether this increased rate of apoptosis observed in the iCE5B&#x02009;+&#x02009;6B GB line was linked to changes in cellular metabolism, we performed a Seahorse Cell Mito Stress Test (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>F, G) to measure the relative oxygen consumption rates (OCR) of the cell lines as an assessment of mitochondrial function. We found that the iCE5B&#x02009;+&#x02009;6B-repressed line presents a significantly higher basal and maximal OCR compared to the control line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>H). This would suggest that these <em>EGFR-</em>enhancer repressed cells are favouring mitochondrial respiration over glycolysis. Based on the same assay, we can also extract that the ATP production and spare respiratory capacity (SRC) of the enhancer-repressed line increased significantly over the control (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>I, J). Moreover, the increased mitochondrial respiratory parameters in the iCE5B&#x02009;+&#x02009;6B cell line are accompanied by significantly increased production of ROS (Reactive Oxygen Species) (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>K) and reduced ratio of reduced glutathione (GSH) to oxidised glutathione (GSSG) (i.e. GSH/GSSG) (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>L), both indicative of increased oxidative stress. We also observed alterations in the expression of several key metabolic genes, including those encoding for lactate dehydrogenase; the TCA cycle enzymes fumarase and malate dehydrogenase, and some subunits of the electron transport chain (ETC) (Supplementary Fig.&#x000a0;S<a href="#MOESM1" rid="MOESM1" class=" media">5</a>). These findings indicate that epigenomic perturbation of the CE5B&#x02009;+&#x02009;6B enhancer region causes increased mitochondrial respiration, resulting in an increased production of ROS, which would contribute to the apoptotic response observed.</p></div><div id="Sec31" class="sec sec-last"><h3 id="Sec31title">Epigenomic perturbation of the <em>EGFR</em> enhancers sensitises glioblastoma cells to TMZ treatment</h3><p id="Par39" class="p p-first-last">Since temozolomide (TMZ) is the first-choice chemotherapeutic agent to treat GB clinically, we wanted to address how the <em>EGFR-</em>enhancer repressed lines respond to treatment with the drug. Not only the combined iCE5B&#x02009;+&#x02009;6B, but also the individual iCE5B, iCE6B and the <em>EGFR</em> iPromoter lines, showed a significantly slower proliferation rate upon TMZ treatment than the DMSO-treated controls (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>B-E and F). On the contrary, the empty vector control line is not significantly affected by TMZ treatment at the used concentration (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>A, F). These findings were also corroborated independently in U3013 GB cells. While the control U3013 cells were not affected by TMZ treatment, the proliferation of iCE5B&#x02009;+&#x02009;6B enhancer-repressed cells was reduced by TMZ at the given dose (Supplementary Fig. S<a href="#MOESM1" rid="MOESM1" class=" media">2</a>C-D). Moreover, TMZ treatment increases the percentage of cleaved caspase-3 positive cell&#x02009;~&#x02009;1.8 times over the DMSO-treated conditions in the control (&#x02205;) line (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>G, H). However, in the iCE5B&#x02009;+&#x02009;6B line, TMZ raises the levels of apoptosis cells&#x02009;~&#x02009;3.3 times over the DMSO-treated condition (Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a> G, H). Therefore, epigenomic repression of <em>EGFR</em> regulatory elements (i.e., novel enhancers and promoter), and subsequent downregulation of <em>EGFR</em> gene expression, sensitises glioblastoma cells to TMZ treatment. Our results show that combining epigenomic perturbation of enhancers or gene promoters with existing cancer drugs could improve the effectiveness of current treatments and subsequently the prognosis of patients.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139733308752688"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10557167_12885_2023_11418_Fig4_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12885_2023_11418_Fig4_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10557167/bin/12885_2023_11418_Fig4_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139733308752688"><a target="object" rel="noopener" href="/pmc/articles/PMC10557167/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC10557167/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Fig. 4</a></div><!--caption a7--><div class="caption"><p>Epigenomic repression of the novel <em>EGFR</em> enhancers sensitises U251 cells to temozolomide (TMZ) treatment. <strong>A</strong>-<strong>E</strong>, Proliferation rates of the <em>EGFR</em> enhancer-repressed lines determined by live-cell imaging upon treatment with 1&#x000a0;mM TMZ in comparison with the DMSO-treated control. Images were acquired every 4&#x000a0;h and proliferation was determined by automatic cell count. Data is normalized to t&#x02009;=&#x02009;0&#x000a0;h and represented as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;3). <em>P</em> values were determined by unpaired <em>t</em> test (* <em>P</em>&#x02009;&#x0003c;&#x02009;0.05, ** <em>P</em>&#x02009;&#x0003c;&#x02009;0.01). <strong>F</strong>, Representative images of control, iCE5B, iCE6B, iCE5B&#x02009;+&#x02009;6B and iPromoter cells upon TMZ treatment in comparison to DMSO-treated controls at t&#x02009;=&#x02009;72&#x000a0;h. <strong>G</strong>, Percent of cleaved caspase-3 positive cells, determined by immunofluorescence, after 48&#x000a0;h treatment with TMZ (1&#x000a0;mM) <em>vs</em> DMSO. Data is plotted as mean&#x02009;&#x000b1;&#x02009;SEM (<em>n</em>&#x02009;=&#x02009;6). <em>P</em> values were determined by unpaired <em>t</em> test (*** <em>P</em>&#x02009;&#x0003c;&#x02009;0.001, **** <em>P</em>&#x02009;&#x0003c;&#x02009;0.0001). <strong>H</strong>, Representative images of cleaved caspase-3 positive apoptotic cells in the iCE5B&#x02009;+&#x02009;6B line following 48&#x000a0;h treatment with TMZ (1&#x000a0;mM). Scale bars 50&#x000a0;&#x003bc;m</p></div></div></div></div></div><div id="Sec32" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec32title">Discussion</h2><p id="Par40" class="p p-first">This study identified novel enhancers that drive the expression of <em>EGFR</em> in glioblastoma cells. CRISPR-mediated (epi-)genomic perturbation (i.e., repression, deletion) of these enhancer regions has a direct effect on the survivability and invasiveness of glioblastoma cells. By specifically repressing the CE5B&#x02009;+&#x02009;6B enhancer region that encompasses the known GB-associated SNP rs723527, we can lower <em>EGFR</em> expression levels and modulate the aggressiveness of glioblastoma cells, which become less proliferative and invasive.</p><p id="Par41">One underlying component of this is an apparent shift in the cellular metabolism upon enhancer perturbation and subsequent <em>EGFR</em> downregulation. The <em>EGFR</em> iCE5B&#x02009;+&#x02009;6B cells increase their basal and maximal mitochondrial respiratory activity, indicating a shift from the typical preference for glycolysis that is a common hallmark of cancerous cells [<a href="#CR21" rid="CR21" class=" bibr popnode">21</a>&#x02013;<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>]. Higher mitochondrial respiration rates result in greater production of reactive oxygen species (ROS), which in turn can inhibit cell growth, damage cellular components and induce cell death [<a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR25" rid="CR25" class=" bibr popnode">25</a>]. Deregulation of ROS production and ROS limitation pathways are common features of cancer cells [<a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. The metabolic rewiring in favour of mitochondrial respiration that we observe in the <em>EGFR</em> iCE5B&#x02009;+&#x02009;6B cells is accompanied by an increased accumulation of ROS and, subsequently, an increase in apoptotic events. This ultimately contributes to a reduction of cell proliferation upon repression of the <em>EGFR</em> enhancers in glioblastoma.</p><p id="Par42">In addition, there is a known bidirectional crosstalk between metabolism and epigenetics such that they reciprocally modulate each other in cancer [<a href="#CR27" rid="CR27" class=" bibr popnode">27</a>, <a href="#CR28" rid="CR28" class=" bibr popnode">28</a>]. Therefore, one could speculate that the epigenomic perturbations that we introduced in the <em>EGFR</em> enhancer could underlie the observed metabolic switch through a mechanism to be determined. Recent reports have pointed the relevance of different metabolic pathways in GB, as drivers of chemoresistance [<a href="#CR29" rid="CR29" class=" bibr popnode">29</a>] or by promoting immunosuppression during tumour evolution [<a href="#CR30" rid="CR30" class=" bibr popnode">30</a>]. Besides, modulating energy metabolism to achieve antitumoral effects is emerging as a potential therapy for GB patients [<a href="#CR31" rid="CR31" class=" bibr popnode">31</a>].</p><p id="Par43">Migration of cancer cells in response to chemical stimuli is an important mechanism in the tumour dissemination process, both locally and during metastatic progression [<a href="#CR32" rid="CR32" class=" bibr popnode">32</a>]. The tumour-associated microglia and macrophages (TAMs) present in the GB tumour microenvironment release growth factors and cytokines, including EGF (Epidermal Growth Factor) and CSF-1, which can promote tumour proliferation, survival and invasion [<a href="#CR33" rid="CR33" class=" bibr popnode">33</a>, <a href="#CR34" rid="CR34" class=" bibr popnode">34</a>]. Our <em>EGFR</em> enhancer-repressed glioblastoma cells also present a reduced response to chemo-attractive stimuli and express less <em>EGFR</em> than the parental unmodified cells. One could therefore speculate that in vivo they might be less responsive to EGF being secreted by macrophages in the tumour microenvironment and could therefore be less invasive.</p><p id="Par44">Repressing the CE5B&#x02009;+&#x02009;6B <em>EGFR</em> enhancer reduces the proliferative and invasive capacity of GB cells, therefore ameliorating the malignant phenotype of glioblastoma cells, while additionally sensitising the cells to temozolomide: the current chemotherapeutic of choice in the clinic. The nature of the relationship between <em>EGFR</em> amplification levels and the response to TMZ treatment remains inconclusive and under debate [<a href="#CR35" rid="CR35" class=" bibr popnode">35</a>]. In our study, upon enhancer repression, lower <em>EGFR</em> levels correlate with an improved response to TMZ, at least in part due to an enhanced apoptotic response. Our findings point to an increased effect of temozolomide in combination with <em>EGFR</em> enhancer perturbation that may provide an effective combination therapy.</p><p id="Par45">While EGFR as a therapeutic target has so far proven clinically unsuccessful in GB [<a href="#CR36" rid="CR36" class=" bibr popnode">36</a>], lessons should be learnt through the limitations of previous trials. Poor blood brain barrier (BBB) penetrance of drugs, a lack of patient stratification based on <em>EGFR</em> mutation status, studies performed primarily in the recurrent disease setting, and a lack of sustained EGFR inhibition have all contributed to a poor therapeutic response [<a href="#CR37" rid="CR37" class=" bibr popnode">37</a>]. In light of this, EGFR should not be neglected as a potential therapeutic target in GB and our findings can help to open up new therapeutic possibilities.</p><p id="Par46" class="p p-last">Taken together, our data highlights the functional importance of the <em>EGFR</em> regulatory genome in glioblastoma and it demonstrates the potential of enhancer modulation as a therapeutic strategy. In the future, the combination of epigenomic perturbation of enhancers and current anti-cancer drugs can improve their effectiveness and subsequently the prognosis of difficult-to-treat cancers, such as glioblastoma.</p></div><div id="sec-a.i.e" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="headless nomenu"></h2><!--/article/body/sec/--><div id="Sec33" class="sec sec-first-last"><h3 id="Sec33title">Supplementary Information</h3><p class="p p-first-last">
</p><div class="sec suppmat" id="MOESM1"><div class="sup-box half_rhythm" id="media-a.i.e.a.b.a.a"><a href="/pmc/articles/PMC10557167/bin/12885_2023_11418_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl"><strong>Additional file 1: Supplementary Figure 1.</strong> Recruitment of dCas9-KRAB repressor complex leads to enrichment of H3K9me3 at specic targeted sites in U251 cells. A-F, Bar charts depicting the enrichment of H3K9me3, as determined by ChIP-qPCR, at each genomic region (i.e., CE5B, CE6B, CE8, Promoter) and in each of the <em>EGFR</em> enhancer-repressed lines: iCE5B (B), iCE6B (C), iCE5B+6B (D) and iCE8 (E), alongside the iPromoter (F) and control line (A). <strong>Supplementary Figure 2.</strong> CRISPRi of <em>EGFR</em> enhancer CE5B+6B in Human Glioblastoma cell line U3013 downregulates <em>EGFR</em> gene expression, reduces cell proliferation rate, and sensitises cells to temozolomide (TMZ). A, <em>EGFR</em> gene expression as determined by RT-qPCR. B, Proliferation rates of the iCE5B+6B and promoter-repressed U3013 cell lines determined by live-cell imaging. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t=0 and presented as mean &#x000b1; SEM (<em>n</em>=3). Statistical significance was assessed by unpaired <em>t</em> test (* <em>P</em> &#x0003c; 0.05, ** <em>P</em> &#x0003c; 0.01). C-D, Proliferation rates of control U3013 and iCE5B+6B enhancer-repressed U3013 cells determined by live-cell imaging upon treatment with 125&#x003bc;M TMZ in comparison with the DMSO-treated control. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t=0h and represented as mean &#x000b1; SEM (<em>n</em>=4). <em>P</em> values were determined by unpaired t test. <strong>Supplementary Figure 3.</strong> CRISPR/Cas9-mediated deletion of <em>EGFR</em> enhancers in U251 cells downregulates <em>EGFR</em> gene expression and affects cell proliferation rates. A, Genotyping PCR of the <em>EGFR</em> enhancer-deleted cell lines (&#x00394;CE5B, &#x00394;CE6B, &#x00394;CE5B+6B, &#x00394;CE8) alongside the &#x00394; Promoter and empty vector control lines (left), and schematic outline of the PCR genotyping strategy (right). Note that the wild-type CE5B+6B allele is too large to be amplied under these conditions. Full uncropped gel image presented in Supplementary Figure 6. B, <em>EGFR</em> gene expression levels relative to <em>HPRT</em> in <em>EGFR</em> enhancer-deleted cell lines as determined by RT-qPCR assays. Data is represented as mean &#x000b1; SEM (<em>n</em>=3). Statistical significance as assessed by unpaired <em>t</em> test with Welch&#x02019;s correction (* <em>P</em> &#x0003c; 0.05, ** <em>P</em> &#x0003c; 0.01). C, Cropped western blots showing EGFR protein expression and normalised to GAPDH protein levels (full uncropped blots in Supplementary Figure 6). D, Proliferation rates of cell lines carrying <em>EGFR </em>enhancer deletions or promoter deletions as determined by live-cell imaging, and in comparison to the empty vector control line. Images were acquired every 4 hours and proliferation was determined by automatic cell count. Data is normalised to t= 0h and plotted as mean &#x000b1; SEM (<em>n</em>=3). <strong>Supplementary Figure 4.</strong> CRISPRi of the <em>EGFR</em> enhancer CE5B+6B and promoter compromises the invasive capacity of U251 cells. A, Representative images of the fusion between the fetal brain spheroids and the GFP+ tumour spheres generated from control, iCE5B+6B and iPromoter lines. Scale bars 750&#x000b5;m (0h) and 300&#x000b5;m (2-24h). B, Quantication of fusion events across a pool of independent tumour sphere/brain spheroid confrontation assays (<em>n</em>=10). C, Quantication of invasion frequency between the GFP+ tumour spheres and brain spheroids between 0h and 96h. D, Representative images of invasion/non-invasion between GFP+ tumour spheres and brain spheroids. Scale bar 100&#x000b5;m. Arrowheads point to areas of invasion. E-F, Line plots comparing the rate at which the respective cell lines migrate either from media containing 1%&#x000a0;FBS to 1%&#x000a0;FBS (no-chemoattractant negative control) or from 1%&#x000a0;FBS to 10%&#x000a0;FBS (chemoattractant condition). Migration was assessed by live-cell imaging taking images every hour and migration rate was determined by automatic quantification of the area of migrated cells. Data is represented as mean &#x000b1; SEM (<em>n</em>=3). <strong>Supplementary Figure 5.</strong> Expression of key metabolic genes in the <em>EGFR</em> enhancer-repressed iCE5B+6B cell line. A, Results from qPCR analysis where certain metabolic genes are upregulated in the iCE5B+6B line relative to the control. Gene expression levels are relative to <em>HPRT</em>. <strong>Supplementary Figure 6.</strong> Uncropped western blot and gel images. A-B, Western blot on repressed cell lines (A) and deletion cell lines (B) detecting EGFR and GAPDH expression. Cropped images presented in Figure 1G and Supplementary Figure 3C, respectively. C, Uncropped genotyping gel from enhancer-deletion U251 cell lines. Cropped image presented in Supplementary Figure 3A.</a><sup>(121M, pdf)</sup></div></div><p></p></div></div><div id="ack-a.j.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.j.btitle">Acknowledgements</h2><div class="sec"><p>We acknowledge the Biochemical Imaging Center at Ume&#x000e5; University and the National Microscopy Infrastructure, NMI (VR-RFI 2019-00217) for providing assistance in microscopy, and the Ume&#x000e5; University Flow Cytometry platform for assistance with cell sorting. Seahorse analyses were performed at the Seahorse Platform, Ume&#x000e5; University. We also thank Helena Edlund for providing the pSPAX and pMD2.G plasmids and GAPDH antibody; Lena Gunhaga for the fertilized eggs; and Ulf Ahlgren for the cleaved caspase-3 antibody.</p></div></div><div id="notes-a.j.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.j.ctitle">Authors&#x02019; contributions</h2><p>CA-V designed, performed, analysed and interpreted most of the experiments and wrote the original manuscript draft. IN performed ChIP-qPCR experiments, and contributed to qPCR analysis and image acquisition. SD performed the 3D spheroid assay. AH contributed to data interpretation and manuscript editing. SR designed and supervised the study, secured funding, analysed and interpreted the data, and wrote and edited the final manuscript with input from the other authors.</p></div><div id="notes-a.j.d" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.j.dtitle">Funding</h2><p>Open access funding provided by Umea University. Research in SR&#x02019;s laboratory is supported by the Swedish Research Council (2019&#x02013;01960), the Swedish Cancer Foundation (21 1720), Knut och Alice Wallenbergs Stiftelse (WCMM, Ume&#x000e5;), the Kempe Foundation (SMK-1964.2), as well as the Cancer Research (AMP 19&#x02013;977, AMP 22&#x02013;1091, AMP 23&#x02013;1137) and Lion&#x02019;s Cancer Research Foundations in Northern Sweden (LP 21&#x02013;2290).</p></div><div id="notes-a.j.e" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.j.etitle">Availability of data and materials</h2><p>Data depicted on Fig.&#x000a0;<a href="/pmc/articles/PMC10557167/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>A is available: a) via the UCSC browser for the tracks displaying the GeneHancer interactions and H3K27ac on 7 ENCODE cell lines, or b) retrieved from GEO (Gene Expression Omnibus) with the accession number <a id="__tag_1142058763" class="tag_hotlink" href="/geo/query/acc.cgi?acc=GSE217349" ref="/geo/query/acc.cgi?acc=GSE217349"><span class="tag-json" style="display:none">{"type":"entrez-geo","attrs":{"text":"GSE217349","term_id":"217349"}}</span>GSE217349</a> for the tracks displaying H3K27ac and ATAC in the glioblastoma lines U3008, U3031 and U3039. Other materials can be available from the corresponding author, SR, upon reasonable request.</p></div><div id="notes-a.j.f" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.j.ftitle">Declarations</h2><div>Ethics approval and consent to participate<p id="Par47">Not applicable.</p></div><div>Consent for publication<p id="Par48">Not applicable.</p></div><div>Competing interests<p id="Par49">The authors declare no competing interests.</p></div></div><div id="fn-group-a.j.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.j.atitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.j.a.a"><p class="p p-first"><strong>Publisher&#x02019;s Note</strong></p><p class="p p-last">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></p></div></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (&#x02265; 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. <span><span class="ref-journal">Sci Rep-uk. </span>2020;<span class="ref-vol">10</span>:11622. doi: 10.1038/s41598-020-68011-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7363854/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32669604" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-020-68011-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep-uk&amp;title=Longer-term+(&#x02265;+2+years)+survival+in+patients+with+glioblastoma+in+population-based+studies+pre-+and+post-2005:+a+systematic+review+and+meta-analysis&amp;author=MTC+Poon&amp;author=CLM+Sudlow&amp;author=JD+Figueroa&amp;author=PM+Brennan&amp;volume=10&amp;publication_year=2020&amp;pages=11622&amp;doi=10.1038/s41598-020-68011-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="mixed-citation">Stewart BW, Wild CP. World Cancer Report 2014. International agency for research on cancer, WHO (World Health Organization). 2014. ISBN 978-92-832-0443-5.</span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. <span><span class="ref-journal">Ann Transl Medicine. </span>2015;<span class="ref-vol">3</span>:121.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4481356/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26207249" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Transl+Medicine&amp;title=Current+trends+in+the+surgical+management+and+treatment+of+adult+glioblastoma&amp;author=RM+Young&amp;author=A+Jamshidi&amp;author=G+Davis&amp;author=JH+Sherman&amp;volume=3&amp;publication_year=2015&amp;pages=121&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. <span><span class="ref-journal">JAMA. </span>2017;<span class="ref-vol">318</span>:2306–2316. doi: 10.1001/jama.2017.18718.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5820703/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29260225" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjama.2017.18718" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect+of+tumor-treating+fields+plus+maintenance+Temozolomide+vs+maintenance+Temozolomide+alone+on+survival+in+patients+with+glioblastoma:+a+randomized+clinical+trial&amp;author=R+Stupp&amp;author=S+Taillibert&amp;author=A+Kanner&amp;author=W+Read&amp;author=DM+Steinberg&amp;volume=318&amp;publication_year=2017&amp;pages=2306-2316&amp;pmid=29260225&amp;doi=10.1001/jama.2017.18718&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. <span><span class="ref-journal">JAMA. </span>2015;<span class="ref-vol">314</span>:2535–2543. doi: 10.1001/jama.2015.16669.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26670971" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjama.2015.16669" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Maintenance+therapy+with+tumor-treating+fields+plus+Temozolomide+vs+Temozolomide+alone+for+glioblastoma:+a+randomized+clinical+trial&amp;author=R+Stupp&amp;author=S+Taillibert&amp;author=AA+Kanner&amp;author=S+Kesari&amp;author=DM+Steinberg&amp;volume=314&amp;publication_year=2015&amp;pages=2535-2543&amp;pmid=26670971&amp;doi=10.1001/jama.2015.16669&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="mixed-citation">The National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in adults NICE guideline [NG99]. 2018. <a href="https://www.nice.org.uk/guidance/ng99" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">https://www.nice.org.uk/guidance/ng99</a>. [<a href="https://pubmed.ncbi.nlm.nih.gov/31393680" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating fields therapy for glioblastoma: current advances and future directions. <span><span class="ref-journal">Br J Cancer. </span>2021;<span class="ref-vol">124</span>:697–709. doi: 10.1038/s41416-020-01136-5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7884384/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33144698" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41416-020-01136-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=Tumour+treating+fields+therapy+for+glioblastoma:+current+advances+and+future+directions&amp;author=O+Rominiyi&amp;author=A+Vanderlinden&amp;author=SJ+Clenton&amp;author=C+Bridgewater&amp;author=Y+Al-Tamimi&amp;volume=124&amp;publication_year=2021&amp;pages=697-709&amp;pmid=33144698&amp;doi=10.1038/s41416-020-01136-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="mixed-citation">Guzauskas GF, Pollom EL, Stieber VW, Wang BCM Jr, LPG. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J M&#x000e9;d Econ. 2019;22:1006&#x02013;13. [<a href="https://pubmed.ncbi.nlm.nih.gov/31050315" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Hegi ME, Annie-Claire D, Thierry G, Marie-France H, de Nicolas T, Michael W, et al. MGMT Gene silencing and benefit from Temozolomide in glioblastoma. <span><span class="ref-journal">New Engl J Med. </span>2005;<span class="ref-vol">352</span>:997–1003. doi: 10.1056/NEJMoa043331.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15758010" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa043331" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&amp;title=MGMT+Gene+silencing+and+benefit+from+Temozolomide+in+glioblastoma&amp;author=ME+Hegi&amp;author=D+Annie-Claire&amp;author=G+Thierry&amp;author=H+Marie-France&amp;author=T+de+Nicolas&amp;volume=352&amp;publication_year=2005&amp;pages=997-1003&amp;pmid=15758010&amp;doi=10.1056/NEJMoa043331&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <span><span class="ref-journal">Neuro-oncology Adv. </span>2020;<span class="ref-vol">2</span>:vdaa082. doi: 10.1093/noajnl/vdaa082.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7596890/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33150334" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnoajnl%2Fvdaa082" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro-oncology+Adv&amp;title=Characterizing+benefit+from+temozolomide+in+MGMT+promoter+unmethylated+and+methylated+glioblastoma:+a+systematic+review+and+meta-analysis&amp;author=I+Alnahhas&amp;author=M+Alsawas&amp;author=A+Rayi&amp;author=JD+Palmer&amp;author=R+Raval&amp;volume=2&amp;publication_year=2020&amp;pages=vdaa082&amp;doi=10.1093/noajnl/vdaa082&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, et al. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. <span><span class="ref-journal">Oncogene. </span>2020;<span class="ref-vol">39</span>:3041–3055. doi: 10.1038/s41388-020-1208-5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7142016/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32066879" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41388-020-1208-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=EGFRvIII+upregulates+DNA+mismatch+repair+resulting+in+increased+temozolomide+sensitivity+of+MGMT+promoter+methylated+glioblastoma&amp;author=N+Struve&amp;author=ZA+Binder&amp;author=LF+Stead&amp;author=T+Brend&amp;author=SJ+Bagley&amp;volume=39&amp;publication_year=2020&amp;pages=3041-3055&amp;pmid=32066879&amp;doi=10.1038/s41388-020-1208-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. <span><span class="ref-journal">Cell. </span>2013;<span class="ref-vol">155</span>:462–477. doi: 10.1016/j.cell.2013.09.034.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3910500/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24120142" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2013.09.034" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The+somatic+genomic+landscape+of+glioblastoma&amp;author=CW+Brennan&amp;author=RGW+Verhaak&amp;author=A+McKenna&amp;author=B+Campos&amp;author=H+Noushmehr&amp;volume=155&amp;publication_year=2013&amp;pages=462-477&amp;pmid=24120142&amp;doi=10.1016/j.cell.2013.09.034&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. <span><span class="ref-journal">Cancer Cell. </span>2010;<span class="ref-vol">17</span>:98–110. doi: 10.1016/j.ccr.2009.12.020.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2818769/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20129251" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ccr.2009.12.020" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Integrated+genomic+analysis+identifies+clinically+relevant+subtypes+of+glioblastoma+characterized+by+abnormalities+in+PDGFRA,+IDH1,+EGFR,+and+NF1&amp;author=RGW+Verhaak&amp;author=KA+Hoadley&amp;author=E+Purdom&amp;author=V+Wang&amp;author=Y+Qi&amp;volume=17&amp;publication_year=2010&amp;pages=98-110&amp;pmid=20129251&amp;doi=10.1016/j.ccr.2009.12.020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Li J, Liang R, Song C, Xiang Y, Liu Y. Prognostic significance of epidermal growth factor receptor expression in glioma patients. <span><span class="ref-journal">Oncotargets Ther. </span>2018;<span class="ref-vol">11</span>:731–742. doi: 10.2147/OTT.S155160.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5808691/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29445288" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2147%2FOTT.S155160" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotargets+Ther&amp;title=Prognostic+significance+of+epidermal+growth+factor+receptor+expression+in+glioma+patients&amp;author=J+Li&amp;author=R+Liang&amp;author=C+Song&amp;author=Y+Xiang&amp;author=Y+Liu&amp;volume=11&amp;publication_year=2018&amp;pages=731-742&amp;doi=10.2147/OTT.S155160&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Sur I, Taipale J. The role of enhancers in cancer. <span><span class="ref-journal">Nat Rev Cancer. </span>2016;<span class="ref-vol">16</span>:483–493. doi: 10.1038/nrc.2016.62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27364481" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc.2016.62" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=The+role+of+enhancers+in+cancer&amp;author=I+Sur&amp;author=J+Taipale&amp;volume=16&amp;publication_year=2016&amp;pages=483-493&amp;pmid=27364481&amp;doi=10.1038/nrc.2016.62&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Remeseiro S, H&#x000f6;rnblad A, Spitz F. Gene regulation during development in the light of topologically associating domains. <span><span class="ref-journal">WIREs Dev Biol. </span>2016;<span class="ref-vol">5</span>:169–185. doi: 10.1002/wdev.218.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26558551" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fwdev.218" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=WIREs+Dev+Biol&amp;title=Gene+regulation+during+development+in+the+light+of+topologically+associating+domains&amp;author=S+Remeseiro&amp;author=A+H&#x000f6;rnblad&amp;author=F+Spitz&amp;volume=5&amp;publication_year=2016&amp;pages=169-185&amp;doi=10.1002/wdev.218&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Schoenfelder S, Fraser P. Long-range enhancer-promoter contacts in gene expression control. <span><span class="ref-journal">Nat Rev Genet. </span>2019;<span class="ref-vol">55</span>:5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31086298" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Genet&amp;title=Long-range+enhancer-promoter+contacts+in+gene+expression+control&amp;author=S+Schoenfelder&amp;author=P+Fraser&amp;volume=55&amp;publication_year=2019&amp;pages=5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="mixed-citation">Zaugg JB, Sahl&#x000e9;n P, Andersson R, Alberich-Jorda M, Laat W de, Deplancke B, et al. Current challenges in understanding the role of enhancers in disease. Nat Struct Mol Biol. 2022;29:1148&#x02013;58. [<a href="https://pubmed.ncbi.nlm.nih.gov/36482255" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Dakhel S, Davies WIL, Joseph JV, Tomar T, Remeseiro S, Gunhaga L. Chick fetal organ spheroids as a model to study development and disease. <span><span class="ref-journal">BMC Mol Cell Biol. </span>2021;<span class="ref-vol">22</span>:37–17. doi: 10.1186/s12860-021-00374-6.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8256237/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34225662" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs12860-021-00374-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Mol+Cell+Biol&amp;title=Chick+fetal+organ+spheroids+as+a+model+to+study+development+and+disease&amp;author=S+Dakhel&amp;author=WIL+Davies&amp;author=JV+Joseph&amp;author=T+Tomar&amp;author=S+Remeseiro&amp;volume=22&amp;publication_year=2021&amp;pages=37-17&amp;pmid=34225662&amp;doi=10.1186/s12860-021-00374-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il&#x02019;yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <span><span class="ref-journal">Nat Genet. </span>2017;<span class="ref-vol">49</span>:789–94. doi: 10.1038/ng.3823.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5558246/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28346443" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fng.3823" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Genome-wide+association+study+of+glioma+subtypes+identifies+specific+differences+in+genetic+susceptibility+to+glioblastoma+and+non-glioblastoma+tumors&amp;author=BS+Melin&amp;author=JS+Barnholtz-Sloan&amp;author=MR+Wrensch&amp;author=C+Johansen&amp;author=D+Il&#x02019;yasova&amp;volume=49&amp;publication_year=2017&amp;pages=789-94&amp;pmid=28346443&amp;doi=10.1038/ng.3823&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Warburg O. &#x000dc;ber den Stoffwechsel der Carcinomzelle. <span><span class="ref-journal">Naturwissenschaften. </span>1924;<span class="ref-vol">12</span>:1131–1137. doi: 10.1007/BF01504608.</span> [<a href="//doi.org/10.1007%2FBF01504608" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Naturwissenschaften&amp;title=&#x000dc;ber+den+Stoffwechsel+der+Carcinomzelle&amp;author=O+Warburg&amp;volume=12&amp;publication_year=1924&amp;pages=1131-1137&amp;doi=10.1007/BF01504608&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? <span><span class="ref-journal">Trends Biochem Sci. </span>2016;<span class="ref-vol">41</span>:211–218. doi: 10.1016/j.tibs.2015.12.001.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4783224/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26778478" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.tibs.2015.12.001" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+Biochem+Sci&amp;title=The+Warburg+effect:+how+does+it+benefit+cancer+cells?&amp;author=MV+Liberti&amp;author=JW+Locasale&amp;volume=41&amp;publication_year=2016&amp;pages=211-218&amp;pmid=26778478&amp;doi=10.1016/j.tibs.2015.12.001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. <span><span class="ref-journal">Nat Metabolism. </span>2020;<span class="ref-vol">2</span>:127–129. doi: 10.1038/s42255-020-0172-2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32694689" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs42255-020-0172-2" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Metabolism&amp;title=We+need+to+talk+about+the+Warburg+effect&amp;author=RJ+DeBerardinis&amp;author=NS+Chandel&amp;volume=2&amp;publication_year=2020&amp;pages=127-129&amp;doi=10.1038/s42255-020-0172-2&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. <span><span class="ref-journal">Nat Rev Mol Cell Bio. </span>2020;<span class="ref-vol">21</span>:363–383. doi: 10.1038/s41580-020-0230-3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32231263" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41580-020-0230-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Mol+Cell+Bio&amp;title=Reactive+oxygen+species+(ROS)+as+pleiotropic+physiological+signalling+agents&amp;author=H+Sies&amp;author=DP+Jones&amp;volume=21&amp;publication_year=2020&amp;pages=363-383&amp;pmid=32231263&amp;doi=10.1038/s41580-020-0230-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Azad N, Iyer AKV.  <span class="ref-journal">Systems Biology of Free Radicals and Antioxidants.</span> 2014. pp. 113–35. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Systems+Biology+of+Free+Radicals+and+Antioxidants&amp;author=N+Azad&amp;author=AKV+Iyer&amp;publication_year=2014&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Cheung EC, Vousden KH. The role of ROS in tumour development and progression. <span><span class="ref-journal">Nat Rev Cancer. </span>2022;<span class="ref-vol">22</span>:280–297. doi: 10.1038/s41568-021-00435-0.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35102280" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41568-021-00435-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=The+role+of+ROS+in+tumour+development+and+progression&amp;author=EC+Cheung&amp;author=KH+Vousden&amp;volume=22&amp;publication_year=2022&amp;pages=280-297&amp;pmid=35102280&amp;doi=10.1038/s41568-021-00435-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Ge T, Gu X, Jia R, Ge S, Chai P, Zhuang A, et al. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. <span><span class="ref-journal">Cancer Commun. </span>2022;<span class="ref-vol">42</span>:1049–1082. doi: 10.1002/cac2.12374.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9648395/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36266736" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fcac2.12374" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Commun&amp;title=Crosstalk+between+metabolic+reprogramming+and+epigenetics+in+cancer:+updates+on+mechanisms+and+therapeutic+opportunities&amp;author=T+Ge&amp;author=X+Gu&amp;author=R+Jia&amp;author=S+Ge&amp;author=P+Chai&amp;volume=42&amp;publication_year=2022&amp;pages=1049-1082&amp;doi=10.1002/cac2.12374&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">Dai Z, Ramesh V, Locasale JW. The evolving metabolic landscape of chromatin biology and epigenetics. <span><span class="ref-journal">Nat Rev Genet. </span>2020;<span class="ref-vol">21</span>:737–753. doi: 10.1038/s41576-020-0270-8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8059378/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32908249" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41576-020-0270-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Genet&amp;title=The+evolving+metabolic+landscape+of+chromatin+biology+and+epigenetics&amp;author=Z+Dai&amp;author=V+Ramesh&amp;author=JW+Locasale&amp;volume=21&amp;publication_year=2020&amp;pages=737-753&amp;pmid=32908249&amp;doi=10.1038/s41576-020-0270-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Shireman JM, Atashi F, Lee G, Ali ES, Saathoff MR, Park CH, et al. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. <span><span class="ref-journal">Brain. </span>2021;<span class="ref-vol">144</span>:1230–1246. doi: 10.1093/brain/awab020.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8105035/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33855339" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fbrain%2Fawab020" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=De+novo+purine+biosynthesis+is+a+major+driver+of+chemoresistance+in+glioblastoma&amp;author=JM+Shireman&amp;author=F+Atashi&amp;author=G+Lee&amp;author=ES+Ali&amp;author=MR+Saathoff&amp;volume=144&amp;publication_year=2021&amp;pages=1230-1246&amp;pmid=33855339&amp;doi=10.1093/brain/awab020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR30">30. <span class="element-citation">Miska J, Rashidi A, Lee-Chang C, Gao P, Lopez-Rosas A, Zhang P, et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. <span><span class="ref-journal">Sci Adv. </span>2021;<span class="ref-vol">7</span>:eabc8929. doi: 10.1126/sciadv.abc8929.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7888943/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33597238" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fsciadv.abc8929" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Adv&amp;title=Polyamines+drive+myeloid+cell+survival+by+buffering+intracellular+pH+to+promote+immunosuppression+in+glioblastoma&amp;author=J+Miska&amp;author=A+Rashidi&amp;author=C+Lee-Chang&amp;author=P+Gao&amp;author=A+Lopez-Rosas&amp;volume=7&amp;publication_year=2021&amp;pages=eabc8929&amp;pmid=33597238&amp;doi=10.1126/sciadv.abc8929&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR31">31. <span class="element-citation">Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q, et al. Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. <span><span class="ref-journal">Neuro-Oncol. </span>2022;<span class="ref-vol">24</span>:1871–1883. doi: 10.1093/neuonc/noac071.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9629419/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35312010" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fneuonc%2Fnoac071" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro-Oncol&amp;title=Blood+exosomes-based+targeted+delivery+of+cPLA2+siRNA+and+metformin+to+modulate+glioblastoma+energy+metabolism+for+tailoring+personalized+therapy&amp;author=Q+Zhan&amp;author=K+Yi&amp;author=X+Cui&amp;author=X+Li&amp;author=S+Yang&amp;volume=24&amp;publication_year=2022&amp;pages=1871-1883&amp;pmid=35312010&amp;doi=10.1093/neuonc/noac071&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR32">32. <span class="element-citation">Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. <span><span class="ref-journal">Nat Rev Cancer. </span>2011;<span class="ref-vol">11</span>:573–587. doi: 10.1038/nrc3078.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4030706/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21779009" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc3078" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&amp;title=Chemotaxis+in+cancer&amp;author=ET+Roussos&amp;author=JS+Condeelis&amp;author=A+Patsialou&amp;volume=11&amp;publication_year=2011&amp;pages=573-587&amp;pmid=21779009&amp;doi=10.1038/nrc3078&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR33">33. <span class="element-citation">Wang G, Zhong K, Wang Z, Zhang Z, Tang X, Tong A, et al. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. <span><span class="ref-journal">Front Immunol. </span>2022;<span class="ref-vol">13</span>:964898. doi: 10.3389/fimmu.2022.964898.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9363573/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35967394" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2022.964898" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Immunol&amp;title=Tumor-associated+microglia+and+macrophages+in+glioblastoma:+From+basic+insights+to+therapeutic+opportunities&amp;author=G+Wang&amp;author=K+Zhong&amp;author=Z+Wang&amp;author=Z+Zhang&amp;author=X+Tang&amp;volume=13&amp;publication_year=2022&amp;pages=964898&amp;pmid=35967394&amp;doi=10.3389/fimmu.2022.964898&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR34">34. <span class="element-citation">Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. <span><span class="ref-journal">Mol Med. </span>2012;<span class="ref-vol">18</span>:519–527. doi: 10.2119/molmed.2011.00217.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3356419/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22294205" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2119%2Fmolmed.2011.00217" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Med&amp;title=Microglial+stimulation+of+glioblastoma+invasion+involves+Epidermal+Growth+Factor+Receptor+(EGFR)+and+Colony+Stimulating+Factor+1+Receptor+(CSF-1R)+Signaling&amp;author=SJ+Coniglio&amp;author=E+Eugenin&amp;author=K+Dobrenis&amp;author=ER+Stanley&amp;author=BL+West&amp;volume=18&amp;publication_year=2012&amp;pages=519-527&amp;pmid=22294205&amp;doi=10.2119/molmed.2011.00217&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR35">35. <span class="element-citation">Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, et al. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. <span><span class="ref-journal">Am J Surg Pathology. </span>2012;<span class="ref-vol">36</span>:1186–1193. doi: 10.1097/PAS.0b013e3182518e12.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3393818/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22472960" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1097%2FPAS.0b013e3182518e12" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Surg+Pathology&amp;title=Paradoxical+relationship+between+the+degree+of+EGFR+amplification+and+outcome+in+glioblastomas&amp;author=J+Hobbs&amp;author=MN+Nikiforova&amp;author=DW+Fardo&amp;author=S+Bortoluzzi&amp;author=K+Cieply&amp;volume=36&amp;publication_year=2012&amp;pages=1186-1193&amp;doi=10.1097/PAS.0b013e3182518e12&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR36">36. <span class="element-citation">Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <span><span class="ref-journal">Lancet Oncol. </span>2017;<span class="ref-vol">18</span>:1373–1385. doi: 10.1016/S1470-2045(17)30517-X.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28844499" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1470-2045(17)30517-X" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Rindopepimut+with+temozolomide+for+patients+with+newly+diagnosed,+EGFRvIII-expressing+glioblastoma+(ACT+IV):+a+randomised,+double-blind,+international+phase+3+trial&amp;author=M+Weller&amp;author=N+Butowski&amp;author=DD+Tran&amp;author=LD+Recht&amp;author=M+Lim&amp;volume=18&amp;publication_year=2017&amp;pages=1373-1385&amp;pmid=28844499&amp;doi=10.1016/S1470-2045(17)30517-X&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR37">37. <span class="element-citation">Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, et al. EGFR, the Lazarus target for precision oncology in glioblastoma. <span><span class="ref-journal">Neuro-Oncol. </span>2022;<span class="ref-vol">24</span>:2035–2062. doi: 10.1093/neuonc/noac204.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9713527/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36125064" ref="reftype=pubmed&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fneuonc%2Fnoac204" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuro-Oncol&amp;title=EGFR,+the+Lazarus+target+for+precision+oncology+in+glioblastoma&amp;author=B+Lin&amp;author=J+Ziebro&amp;author=E+Smithberger&amp;author=KR+Skinner&amp;author=E+Zhao&amp;volume=24&amp;publication_year=2022&amp;pages=2035-2062&amp;pmid=36125064&amp;doi=10.1093/neuonc/noac204&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10557167&amp;issue-id=425102&amp;journal-id=16&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">BMC Cancer</span> are provided here courtesy of <strong>BMC</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10557167/pdf/12885_2023_Article_11418.pdf" class="int-view">PDF (3.5M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10557167/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10557167/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10557167" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="k1242Y845XPq5tUK2OFYMjwSQvGe59uZrJ3mVsa6wAt9nbNpk1mlrHZ5kYCVSbN6">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F&amp;text=Epigenomic%20perturbation%20of%20novel%20EGFR%20enhancers%20reduces%20the%20proliferative%20and%20invasive%20capacity%20of%20glioblastoma%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10557167%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557167/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37803333/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37803333/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10557167/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10557167/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10557167/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
